New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
10:12 EDTECYT, INSM, CONN, FIVE, LULUOptions with decreasing implied volatility: ECYT INSM CONN FIVE LULU
News For ECYT;INSM;CONN;FIVE;LULU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:28 EDTINSMLeerink to hold a roundtable
Subscribe for More Information
07:25 EDTLULUTelsey Advisory to hold a conference
Subscribe for More Information
September 30, 2014
12:59 EDTCONNLuxor Capital Group reports 20.9% stake in Conn's
Subscribe for More Information
10:59 EDTLULUlululemon management to meet with Oppenheimer
Subscribe for More Information
10:02 EDTECYTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:05 EDTLULUStocks with implied volatility below IV index mean; LULU NKE
Stocks with implied volatility below IV index mean; lululemon (LULU) 31, Nike (NKE) 18 according to iVolatility.
05:28 EDTECYTEndocyte downgraded to Hold from Buy at Brean Capital
Brean Capital downgraded Endocyte to Hold saying it views the company's data for vintafolide as "marginal."
September 29, 2014
06:27 EDTECYTEndocyte to host conference call
Subscribe for More Information
06:08 EDTLULUStocks with implied volatility below IV index mean; LULU HD
Stocks with implied volatility below IV index mean; lululemon (LULU) 31, Home Depot (HD) 16 according to iVolatility.
September 28, 2014
14:12 EDTECYTEndocyte says Phase 2b TARGET trial results show improved survival
Endocyte announced that the small molecule drug conjugate, SMDC, vintafolide in combination with docetaxel extended overall survival for patients with folate receptor positive recurrent non-small cell lung cancer, NSCLC, compared to patients receiving monotherapy docetaxel in its TARGET Phase 2b clinical trial. The late-breaking TARGET trial data will be presented today at the European Society for Medical Oncology Congress, ESMO, by Rohit Lal, M.D., consultant medical oncologist at Guys and St Thomas' Hospital and an Honorary Consultant Medical Oncologist for Kings College Hospital, London.
September 26, 2014
06:09 EDTLULUStocks with implied volatility below IV index mean; LULU HD
Subscribe for More Information
September 19, 2014
07:40 EDTLULUVF Corp. upgraded to Buy, could target lululemon, says KeyBanc
As previously reported, KeyBanc upgraded VF Corp (VFC) to Buy from Hold with an $80 price target. The firm cited momentum at its Timberland brand, VF's strong brand portfolio, and the potential for another large M&A transaction. The analyst said VF Corp. is well positioned to complete another large deal and could target lululemon (LULU). KeyBanc believes lululemon's quality issues, forecasting and store operational challenges play into VF Corp.'s strengths and that such an acquisition would be 10c accretive initially and 80c accretive over time.
September 18, 2014
09:36 EDTCONNConn's to host analyst and investor day
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use